Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,738 shares of the biopharmaceutical company’s stock after acquiring an additional 10,235 shares during the quarter. Aberdeen Group plc owned approximately 0.15% of Regeneron Pharmaceuticals worth $124,841,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in REGN. Meyer Handelman Co. increased its stake in Regeneron Pharmaceuticals by 0.6% in the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after buying an additional 18 shares during the period. CoreCap Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 20 shares during the period. Strait & Sound Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 21 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Regeneron Pharmaceuticals by 14.8% in the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 21 shares during the last quarter. Finally, MAI Capital Management increased its stake in shares of Regeneron Pharmaceuticals by 2.1% in the third quarter. MAI Capital Management now owns 1,028 shares of the biopharmaceutical company’s stock worth $578,000 after acquiring an additional 21 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 2.0%

REGN opened at $761.85 on Friday. The firm has a market cap of $80.54 billion, a P/E ratio of 18.33, a price-to-earnings-growth ratio of 2.09 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The business has a 50 day moving average price of $766.46 and a 200 day moving average price of $711.65. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the company posted $12.07 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EYLEA HD FDA approval — The FDA cleared EYLEA HD (aflibercept) with dosing intervals up to five months for wAMD and DME, which could expand patient adherence, differentiate Regeneron’s retina franchise and reduce treatment burden; this is a near‑term commercial tailwind for recurring ophthalmology revenue. EYLEA HD® (aflibercept) Approved by FDA
• Positive Sentiment: TriNetX collaboration — Regeneron gained exclusive ability to link its large genomic/proteomic cohorts to TriNetX’s ~300M de‑identified EHR records, accelerating AI training, target validation and digital‑health product development; this strengthens data advantages that can speed discovery and improve long‑term R&D productivity. TriNetX Collaborates with Regeneron
• Positive Sentiment: Regeneron expects to avoid U.S. pharma tariffs — Management told Reuters it expects to be excluded from proposed tariff lists, which reduces the risk of a direct near‑term hit to margins or pricing for REGN relative to peers. Regeneron says it expects to avoid new US pharma tariffs
• Neutral Sentiment: Piper Sandler starts coverage — New analyst coverage can increase visibility and liquidity; impact depends on the firm’s initial rating and research cadence. Piper Sandler Begins Coverage on Regeneron
• Neutral Sentiment: Sector R&D headlines (Bayer/AskBio) — Industry pipeline progress at peers underscores broader biopharma innovation but has no direct Regeneron tie; useful context for sector allocation decisions. Bayer Advances AB-1002 Study
• Negative Sentiment: Analyst pressure — Truist lowered its price target to $801, which can prompt short‑term selling and weigh on sentiment despite the stock’s valuation metrics. Truist Lowers Regeneron Price Target
• Negative Sentiment: Broader tariff moves raise sector risk — Administration proposals for high tariffs on branded drugs are creating uncertainty across pharma; even though Regeneron expects exclusion, the policy remains a headline risk that can pressure sector multiples. Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Analyst Upgrades and Downgrades

Several brokerages have weighed in on REGN. Evercore upped their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $804.70.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock worth $4,142,738 in the last 90 days. Insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.